Figure 1 (Revatio 01)
Sildenafil For Oral Suspension
Product Images NDC 72205-035
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Sildenafil For Oral Suspension (NDC 72205-035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 (Revatio 02)
Figure 3 (Revatio 03)
Figure 4 (Revatio 04)
Figure 5 (Revatio 05)
Figure 6 (Revatio 06)
Chemical Structure (Revatio 07)
Figure 7 (Revatio 08)
This document provides information on drug interactions, particularly on their fold change and 90% confidence interval recommendation. It specifies the need for no dose adjustment when taking Atorvastatin and Azithromycin. However, taking Bosentan is not recommended, while for Cimetidine, it is recommended to not make a dose adjustment. For Ritonavir, its administration with sildenafil is not recommended, while Saquinavir requires no dose adjustment. The document also features a graph that shows the change in vertical solid line concerning Sildenafil alone. Additionally, it specifies the AUC accumulation ratio from Day 1 to Day 7 relative to sildenafil alone, but it reminds readers that there is no benefit on exercise capacity when sildenafil is added to bosentan therapy, as seen in Clinical Studies.*
Figure 8 (Revatio 09)
This is a list of drugs that have the potential to interact with Acenocoumarol. The effects of the interactions are shown in the columns "INR AUC," "INR Cmax," "BT," "AuC," and "Cmax." The recommendation for each interaction is displayed in the "Recommendation" column. Some of the drugs require no dose adjustment, while others are not recommended for co-administration. Doxazosin and sildenafil may increase the efficacy of Acenocoumarol by 95%. The text also notes that sildenafil therapy is enhanced when used alone, and potentially reduced when used with bosentan or ritonavir.*
Figure 9 (Revatio 10)
This text appears to be a table or graph depicting changes in meters during a study between different weeks. The horizontal axis represents the different weeks of the study, including Veek 4, Veek 8, and Veek 12. The vertical axis depicts a change from the baseline in meters, with values of 80 and 40. The key provides information on the medication that was administered during the study, including Sildenafil at 40mg TID, Placebo, Sildenafil at 80mg TID, and Sildenafil at 208 TID. It is unclear what the study was examining or measuring.*
Figure 10 (Revatio 11)
Figure 11 (Revatio 12)
Figure 12 (Revatio 13)
This text is a graph description showing the change from baseline in meters for different treatments (Sildenafil ImgTID, Sildenafil SmgTID and Sildenafil 20mg TID) at different weeks up to 12. The graph includes the mean change and standard error for each treatment.*
Figure A (Revatio 15)
The text describes a syringe adaptor and a bottle of REVATIO oral suspension. It also mentions a barrel and a plunger. No further information is available to provide a more detailed description or context.*
Figure B (Revatio 16)
Figure C (Revatio 17)
Figure D (Revatio 18)
Figure E (Revatio 19)
Figure F (Revatio 20)
Figure G (Revatio 21)
Principal Display Panel (10 mg/mL Bottle Label)
This is a description of a prescription-only grape-flavored oral suspension containing 10 mg/mL of sildenafil citrate that needs to be stored below 30°C before reconstitution, after which it can be stored in the refrigerator at 2° to 8°C for up to 60 days. The suspension comes in a bottle that contains 1.12 g of sildenafil citrate and must be discarded after the stated date. The recommended dosage information is provided in the prescribing information. The product is distributed by Novadoz and manufactured by Novadoz Pharmaceuticals LLC, and it requires shaking well before each use. The rest of the text includes contact information for the manufacturers.*
Principal Display Panel (10 mg/mL Bottle Carton)
This is a product information sheet for Sildenafil for Oral Suspension. The medication comes in a bottle containing 1.57g of sildenafil citrate and can be reconstituted with 90 mL of water to create a suspension. The suspension is grape-flavored and should be shaken well before use. The recommended dosage should be followed as per the prescribing information. The medication should be stored below 30°C (86°F) before reconstitution and below 30°C (36°F) or in the refrigerator at 2°-8°C (36°-46°F) after reconstitution. Any unused portion should be discarded after 60 days. The product is manufactured by AptaPharma Inc. and distributed by Novadoz Pharmaceuticals LLC.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
